Report on the questionnaire survey targeting medical centers for dementia about the medical care service system after the introduction of a disease-modifying drug for Alzheimer's disease

Yoshiki Niimi^1）, Toshihisa Tanaka^2）, Shinya Ishii^3）, Kumiko Utsumi^4）, Ayako Edahiro^5）, Akinori Takeda^6）, Hidekazu Tomimoto^7）, Naoki Fujimoto^8）, Kou Furuta^5）, Hiroshi Mori^9）10）, Shuichi Awata^5）, Takeshi Iwatsubo^1）11）

^1）Unit for Early and Exploratory Clinical Development, The University of Tokyo Hospital
^2）Faculty of Medicine, Mie University
^3）Department of Medicine for Integrated Approach to Social Inclusion, Graduate School of Biomedical and Health Sciences, Hiroshima University
^4）Sunagawa City Medical Center
^5）Tokyo Metropolitan Institute for Geriatrics and Gerontology
^6）National Center for Geriatrics and Gerontology
^7）Saiseikai Meiwa Hospital
^8）Fujimoto Clinic
^9）Department of Clinical Neuroscience, Osaka Metropolitan University
^10）Nagaoka Sutoku University
^11）Department of Neuropathology, Graduate School of Medicine, The University of Tokyo

These years, the anti-amyloidβ antibody drug has been approved in the United States as a therapeutic for early-stage Alzheimer's disease （AD）.　The development of disease-modifying drug （DMD） in disease modification of AD is progressing.　Soon, DMD may be available for clinical use in Japan.　However, there are many issues to be discussed in the implementation of clinical use of DMD, such as health economics, imaging and CSF biomarkers, and management of amyloid-related imaging abnormalities （ARIA）.　Given this point, the Social Response Committee and the Dementia Disease Modifiers Special Committee of the Japanese Society for Dementia Research jointly conducted a survey targeting medical centers for dementia.　A self-administered questionnaire was sent by mail to 496 centers nationwide.　We acquired 213 responses （42.9%）.　It revealed that many centers recognize the need for a proper diagnostic test and safety management system in the use of DMD.　However, there are differences in the feasibility of system preparation depending on each center.　The implementation of DMD requires a comprehensive assessment of regional medical resources.

Address correspondence to Dr. Yoshiki Niimi, Unit for Early and Exploratory Clinical Development, The University of Tokyo Hospital （Hongo, Bunkyo-ku, Tokyo, Japan）